Skip to main content
Smart Investors Daily
DN

AMEX · DNL

WisdomTree Global ex-U.S. Quality Dividend Growth Fund

Financial Services · Asset Management - Global

$46.77

Up+$0.24 (+0.52%)

Updated Aug 26, 2026, 6:15 AM

SID Score

4.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
480.63M
P/E ratio
Dividend yield
1.79%
52-week range
$38.38 – $47.46
Volume
14.18K
Avg. volume
68.78K

Price performance

DNL price history

1M range · 21 trading sessions · Daily adjusted prices

DNL closed at $46.77 after 21 trading sessions, up 6.03% for the selected period.

Last close
$46.77
Period change
+6.03%
Period low
$43.98
Period high
$47.24
Daily close
View OHLC price history
DNL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 25, 2026$46.76$46.80$46.6701$46.7714.18K
Aug 24, 2026$46.60$46.60$46.39$46.52810.41K
Aug 21, 2026$46.88$46.89$46.75$46.8911.66K
Aug 20, 2026$46.45$46.64$46.4403$46.5520.91K
Aug 19, 2026$46.87$46.92$46.625$46.692217.19K
Aug 18, 2026$46.57$46.6093$46.25$46.336414.99K
Aug 17, 2026$47.31$47.4183$47.21$47.223234.22K
Aug 14, 2026$47.27$47.27$46.99$47.07026.62K
Aug 13, 2026$47.08$47.33$47.065$47.23911.64K
Aug 12, 2026$47.46$47.46$47.07$47.0712.85K
Aug 11, 2026$47.18$47.3052$46.905$47.018345.92K
Aug 10, 2026$47.01$47.10$46.9401$46.945813.96K
Aug 7, 2026$46.84$46.905$46.61$46.79915.3K
Aug 6, 2026$46.12$46.37$46.05$46.1623.45K
Aug 5, 2026$46.50$46.56$46.24$46.2712.7K
Aug 4, 2026$45.73$46.19$45.73$46.13726.6K
Aug 3, 2026$45.04$45.35$44.935$45.2215.91K
Jul 31, 2026$45.34$45.3451$44.635$44.9623.29K
Jul 30, 2026$44.64$45.30$44.56$45.2317.33K
Jul 29, 2026$43.95$44.4101$43.67$43.9819.89K
Jul 28, 2026$43.87$44.32$43.86$44.119.25K

Latest DNL news

The latest Smart Investors Daily articles mentioning DNL.

DNL research

Overview

Company profile and research snapshot.

Company profile

Under normal circumstances, at least 95% of the fund's total assets (exclusive of collateral held from securities lending) will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is a fundamentally weighted index that consists of dividend-paying global ex-U.S. common stocks with growth characteristics. The fund is non-diversified.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Dec 10, 2025

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tividenofusp alfa is under FDA Priority Review under Accelerated Approval pathway, with PDUFA date extended to April 5, 2026. Company's ETV platform enables expansion into additional lysosomal storage disorders, with DNL126 for MPS IIIA offering near-term catalysts and proof of platform versatility.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.